Author:
Han Ji-Youn,Lee Soo Hyun,Lee Geon Kook,Yun Tak,Lee Young Joo,Hwang Kum Hui,Kim Jin Young,Kim Heung Tae
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference25 articles.
1. Shien K, Toyooka S, Yamamoto H et al (2013) Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res 73:3051–3061
2. Ng KP, Hillmer AM, Chuah CT et al (2012) A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 18:521–528
3. Garassino MC, Martelli O, Broggini M et al (2013) Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 14:981–988
4. Okano Y, Ando M, Asami K, Fukuda M, Nakagawa H, Ibata H, et al. (2013) Randomized phase III trial of erlotinib versus docetaxel as second-or third-line therapy in patients with advanced non-small cell lung cancer who have wild type or mutant EGFR. J Clin Oncol 31 (suppl): abstr 8006
5. Tate CR, Rhodes LV, Segar HC et al (2012) Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res 14:R79
Cited by
50 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献